ClinicalTrials.gg
CompletedNCT00469157Updated Apr 17, 2008

Refractive Surgery and Optive Compatibility Study

A Phase 4 interventional study of Optive in Dry Eye Syndromes, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-17.

Sponsored by Innovative Medical · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.

Enrollment
4th of 11
92 · median 80
Started
2007
the only one that year
Phase 4
11 of 12
2 open now
Registered
4th of 12
by date
Lead sponsor
2 of 12
Innovative Medical

Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 11 in phase 4, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About carboxymethylcellulose

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, or all of them as a file.
02

Study summary

To assess the compatibility of Optive with refractive surgery (PRK and LASIK) post-operatively.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

Keywords

  • compatibility of Optive after PRK or LASIK
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18 and over
  • Patients undergoing refractive surgery

Exclusion criteria

Exclusion Criteria:

  • Concurrent ocular conditions or pathology that could affect patient's ability to complete study
  • Concurrent use of topical medications other than study medications
  • Use of systemic medications with ocular drying sequelae:

    • Antihistamines
    • Decongestants
    • Antispasmotics
    • Antidepressants
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Other
    1.

    Drug: Optive

Interventions

06

What researchers measure

Primary outcomes

  1. Assess compatibility

    Time frame: 8 months

Secondary outcomes

  1. comfort

    Time frame: 8 months

07

Study locations

1 site
  • TLC
    Fullerton, California 92831, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2007
First posted
May 4, 2007
Start
May 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Last update
Apr 17, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00469157
Lead sponsor
Innovative Medical
First posted
May 4, 2007
Start date
May 2007
Primary completion
Apr 2008
Completion
Apr 2008
Last update
Apr 17, 2008

Study contacts

Loren Rude, OD
principal investigator · TLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboxymethylcellulose · Glycerol

Start the discussion